Intellia (NTLA) - Market Cap to Earnings

Corporate emblem and logo of Intellia Therapeutics Inc (NTLA)

Intellia Therapeutics (NTLA) is developing CRISPR therapies to combat rare genetic pathologies. Business growth is independent of economic cycles, relying instead on the success of clinical trials and venture capital. Automated laboratories are accelerating drug development, as reflected in the price-to-earnings dynamics. The value of -3.10 determines this parameter level on this chart.

NTLA - intelliatx.com Price to Earnings Ratio over the range 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for Intellia Corp (NTLA)

- share price and consensus valuation forecast:
- market capitalization indicators:
General company analysis:Intellia - NTLA
Manufactured product of Intellia

Intellia Therapeutics (NTLA), which develops CRISPR technologies through global alliances, demonstrates specific valuation characteristics via the P/E ratio, which correlates market capitalization with net income to determine the payback period of assets. The current value of -3.10 reflects market expectations for future breakthroughs in genome editing; therefore, the issuer's P/E history allows investors to distinguish fundamental growth from speculative overheating of the business value.

Competing companies

tempus.com - Market Cap to Net Income|P/E Multiple QGEN|Business Payback Period Isis Pharmaceuticals|P/E Multiple RGEN (repligen.com)|Market Price to Net Income Ratio RNA (Avidity Biosciences, Inc.)|CRSP - Price to Earnings Ratio|Company Value to Net Income WGS (GeneDx)|RARE: P/E Multiple|Beam Therapeutics Corp - Company Value to Net Income|Price to Earnings Ratio SRPT|twistbioscience.com (TWST) - Business Payback Period|P/E Multiple TXG|STOK - Market Cap to Earnings|Price to Earnings Ratio biolifesolutions.com BLFS|Business Payback Period Wave Life Sciences Corp (WVE)|MAZE - Price to Earnings Ratio|Company Value to Net Income SION (Sionna Therapeutics Inc)|PRME: P/E Multiple|Taysha - Company Value to Net Income|Price to Earnings Ratio uniQure NV|Price to Earnings Multiple MGTX (MeiraGTx PLC)|Price to Earnings Ratio RGNX (regenxbio.com)|Solid Biosciences Inc. - Price to Earnings Multiple|Price to Earnings Ratio Ocugen Corp OCGN|Pacific Biosciences of California, Inc. (PACB) - Market Cap to Earnings|BNTC - Price to Earnings Ratio|Design Pharma - Market Price to Net Income Ratio|RCKT (Rocket Pharmaceuticals Inc) - Price to Earnings Ratio|4D Molecular Therapeutics (FDMT) - P/E Multiple|Price to Earnings Ratio Lexeo Therapeutics, Inc.|Market Cap to Earnings Korro Bio, Inc. KRRO|P/E Multiple EDIT|Business Payback Period Silence Therapeutics Corp|Price to Earnings Ratio proqr.com PRQR|CDXS - Price to Earnings Ratio|SGMO - Price to Earnings Ratio|Market Cap to Net Income Ratio Nautilus Biotechnology, Inc. (NAUT)|MGX: P/E Multiple|Price to Earnings Multiple DTIL|GBIO (Generation Bio) - P/E Multiple|Price to Earnings Multiple BOLD (boundlessbio.com)|Price to Earnings Ratio XCUR (exicuretx.com)|Celsion Corporation - Price to Earnings Multiple|P/E Multiple PHIO (phiopharma.com)|P/E Multiple Mustang Bio, Inc. MBIO|RNAZ: Price to Earnings Ratio|BNGO (Bionano Genomics) - Price to Earnings Multiple|APDN: P/E Multiple|bluebird bio (BLUE) - P/E Multiple|Price to Earnings Ratio ImmunoPrecise Antibodies Ltd.|Market Cap to Earnings Omega OMGA|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Syros Pharmaceuticals, Inc - Price to Earnings Ratio|Business Payback Period Codex DNA (TBIO)|TCON - Price to Earnings Ratio|UBX: Price to Earnings Ratio